Recursion Pharmaceuticals (RXRX) Deferred Taxes (2025 - 2026)

Recursion Pharmaceuticals (RXRX) posted Deferred Taxes of -$4.6 million for Q1 2026, down 997.14% on a QoQ basis from -$419000.0 in Q1 2025, and down 997.14% year-over-year from $512408.4 in Q1 2025.

Recursion Pharmaceuticals (RXRX) Deferred Taxes (2025 - 2026) Analysis & Trends

Recursion Pharmaceuticals' Deferred Taxes history runs 2 years deep, the most recent figure standing at -$4.6 million for Q1 2026.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Deferred Taxes (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn -
4 NuCana 279.75 Bn 279.75 Bn - -188,883.60
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn -65.30 Mn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 96.00 Mn
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 Recursion Pharmaceuticals 1.59 Bn 933.22 Mn -6.02 Mn -4.60 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -4.60 Mn
Mar 31, 2025 -419,000.00